Abstract
Medicare beneficiaries filling oral anticancer drug prescriptions often have expected annual out-of-pocket costs exceeding $10,000 [1]. Cost-related prescription non-initiation affects almost 1 in 3 Medicare beneficiaries (without low-income subsidies) prescribed high-cost specialty anticancer drugs [2]. While longer-term policy solutions are implemented, there is an urgent need to explore “on-the-ground” affordability solutions. It is unknown how altering medication prescribing could reduce out-of-pocket costs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
